信达生物(01801.HK)获摩根大通增持134.55万股

Group 1 - JPMorgan Chase & Co. increased its stake in Innovent Biologics (01801.HK) by acquiring 1.345 million shares at an average price of HKD 90.0345 per share, totaling approximately HKD 121 million [1] - Following the acquisition, JPMorgan's total holdings in Innovent Biologics rose to 87,775,465 shares, increasing its ownership percentage from 4.98% to 5.06% [1]